Switch to:
Also traded in: Germany, India, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.35
RDY's Cash-to-Debt is ranked lower than
77% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. RDY: 0.35 )
Ranked among companies with meaningful Cash-to-Debt only.
RDY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1  Med: 0.71 Max: No Debt
Current: 0.35
Equity-to-Asset 0.53
RDY's Equity-to-Asset is ranked lower than
66% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. RDY: 0.53 )
Ranked among companies with meaningful Equity-to-Asset only.
RDY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.56 Max: 0.82
Current: 0.53
0.31
0.82
Interest Coverage 48.23
RDY's Interest Coverage is ranked higher than
50% of the 635 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. RDY: 48.23 )
Ranked among companies with meaningful Interest Coverage only.
RDY' s Interest Coverage Range Over the Past 10 Years
Min: 2.17  Med: 20.43 Max: 79.57
Current: 48.23
2.17
79.57
Piotroski F-Score: 6
Altman Z-Score: 3.98
Beneish M-Score: -1.78
WACC vs ROIC
2.92%
12.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 16.65
RDY's Operating Margin % is ranked higher than
97% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. RDY: 16.65 )
Ranked among companies with meaningful Operating Margin % only.
RDY' s Operating Margin % Range Over the Past 10 Years
Min: -4.08  Med: 17.49 Max: 42.48
Current: 16.65
-4.08
42.48
Net Margin % 8.69
RDY's Net Margin % is ranked higher than
55% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. RDY: 8.69 )
Ranked among companies with meaningful Net Margin % only.
RDY' s Net Margin % Range Over the Past 10 Years
Min: -7.44  Med: 14.38 Max: 16.28
Current: 8.69
-7.44
16.28
ROE % 10.15
RDY's ROE % is ranked higher than
58% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. RDY: 10.15 )
Ranked among companies with meaningful ROE % only.
RDY' s ROE % Range Over the Past 10 Years
Min: -11.56  Med: 23.4 Max: 29.21
Current: 10.15
-11.56
29.21
ROA % 5.78
RDY's ROA % is ranked higher than
58% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. RDY: 5.78 )
Ranked among companies with meaningful ROA % only.
RDY' s ROA % Range Over the Past 10 Years
Min: -6.1  Med: 12.11 Max: 13.77
Current: 5.78
-6.1
13.77
ROC (Joel Greenblatt) % 17.62
RDY's ROC (Joel Greenblatt) % is ranked higher than
56% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. RDY: 17.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RDY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7.46  Med: 32.37 Max: 65.25
Current: 17.62
-7.46
65.25
3-Year Revenue Growth Rate 10.20
RDY's 3-Year Revenue Growth Rate is ranked higher than
63% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. RDY: 10.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RDY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.4  Med: 15 Max: 46.1
Current: 10.2
0.4
46.1
3-Year EBITDA Growth Rate 12.20
RDY's 3-Year EBITDA Growth Rate is ranked higher than
56% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. RDY: 12.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RDY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -37  Med: 14.5 Max: 154.4
Current: 12.2
-37
154.4
3-Year EPS without NRI Growth Rate 8.20
RDY's 3-Year EPS without NRI Growth Rate is ranked higher than
52% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. RDY: 8.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RDY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -65  Med: 24.7 Max: 154.7
Current: 8.2
-65
154.7
GuruFocus has detected 1 Warning Sign with Dr Reddy's Laboratories Ltd $RDY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RDY's 30-Y Financials

Financials (Next Earnings Date: 2017-08-12 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

RDY Guru Trades in Q2 2016

Jim Simons 132,300 sh (+444.44%)
Ken Fisher 5,227,024 sh (+9.46%)
Jeremy Grantham 80,200 sh (-7.50%)
Sarah Ketterer 294,600 sh (-22.51%)
» More
Q3 2016

RDY Guru Trades in Q3 2016

Ken Fisher 5,696,909 sh (+8.99%)
Jim Simons Sold Out
Sarah Ketterer 191,543 sh (-34.98%)
Jeremy Grantham 50,200 sh (-37.41%)
» More
Q4 2016

RDY Guru Trades in Q4 2016

Sarah Ketterer 217,943 sh (+13.78%)
Ken Fisher 5,621,898 sh (-1.32%)
Jeremy Grantham 35,000 sh (-30.28%)
» More
Q1 2017

RDY Guru Trades in Q1 2017

Jim Simons 110,223 sh (New)
Jeremy Grantham Sold Out
Ken Fisher 5,552,562 sh (-1.23%)
Sarah Ketterer 197,886 sh (-9.20%)
» More
» Details

Insider Trades

Latest Guru Trades with RDY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:HKMPY, OTCPK:HYPMY, NYSE:PTHN, NYSE:VRX, NYSE:TARO, OTCPK:STDAF, OTCPK:APNHF, NYSE:CTLT, NAS:AKRX, NYSE:MNK, NAS:OPK, OTCPK:HLUYY, OTCPK:IPSEY, NYSE:PRGO, OTCPK:SFOSF, NAS:MDCO, NAS:ENDP, NAS:IRWD, OTCPK:SWPIF, NAS:PCRX » details
Traded in other countries:RDDA.Germany, 500124.India, RDY N.Mexico,
Headquarter Location:India
Dr Reddy's Laboratories Ltd together with its subsidiaries is engaged in manufacturing of pharmaceutical products. It operates through three segments; Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products.

With headquarters in India, Dr. Reddy's Laboratories develops and manufactures generic pharmaceuticals. The firm operates in three divisions: global generics, proprietary products, and active chemical ingredients. The global generics and pharmaceutical services and active ingredients segments make up most of the company's revenue at about 80% and 17%, respectively. About 85% of Dr. Reddy's sales are based outside of India, with approximately 48% from North America and 12% from Europe.

Ratios

vs
industry
vs
history
PE Ratio 33.47
RDY's PE Ratio is ranked lower than
63% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.48 vs. RDY: 33.47 )
Ranked among companies with meaningful PE Ratio only.
RDY' s PE Ratio Range Over the Past 10 Years
Min: 10.61  Med: 23.43 Max: 361.99
Current: 33.47
10.61
361.99
Forward PE Ratio 18.38
RDY's Forward PE Ratio is ranked lower than
73% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. RDY: 18.38 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 33.47
RDY's PE Ratio without NRI is ranked lower than
66% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.85 vs. RDY: 33.47 )
Ranked among companies with meaningful PE Ratio without NRI only.
RDY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.61  Med: 23.43 Max: 361.99
Current: 33.47
10.61
361.99
Price-to-Owner-Earnings 78.73
RDY's Price-to-Owner-Earnings is ranked lower than
82% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. RDY: 78.73 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
RDY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.47  Med: 62.13 Max: 741.9
Current: 78.73
11.47
741.9
PB Ratio 3.31
RDY's PB Ratio is ranked lower than
55% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. RDY: 3.31 )
Ranked among companies with meaningful PB Ratio only.
RDY' s PB Ratio Range Over the Past 10 Years
Min: 1.27  Med: 4.62 Max: 6.72
Current: 3.31
1.27
6.72
PS Ratio 2.85
RDY's PS Ratio is ranked higher than
52% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. RDY: 2.85 )
Ranked among companies with meaningful PS Ratio only.
RDY' s PS Ratio Range Over the Past 10 Years
Min: 0.94  Med: 3.13 Max: 4.84
Current: 2.85
0.94
4.84
Price-to-Operating-Cash-Flow 18.25
RDY's Price-to-Operating-Cash-Flow is ranked lower than
52% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. RDY: 18.25 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RDY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.8  Med: 20.65 Max: 166.22
Current: 18.25
6.8
166.22
EV-to-EBIT 29.86
RDY's EV-to-EBIT is ranked lower than
71% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. RDY: 29.86 )
Ranked among companies with meaningful EV-to-EBIT only.
RDY' s EV-to-EBIT Range Over the Past 10 Years
Min: -531.5  Med: 18.55 Max: 276.7
Current: 29.86
-531.5
276.7
EV-to-EBITDA 19.29
RDY's EV-to-EBITDA is ranked lower than
55% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. RDY: 19.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
RDY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -43.5  Med: 14.7 Max: 75.1
Current: 19.29
-43.5
75.1
PEG Ratio 2.12
RDY's PEG Ratio is ranked lower than
55% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.90 vs. RDY: 2.12 )
Ranked among companies with meaningful PEG Ratio only.
RDY' s PEG Ratio Range Over the Past 10 Years
Min: 0.3  Med: 0.99 Max: 5.18
Current: 2.12
0.3
5.18
Shiller PE Ratio 33.98
RDY's Shiller PE Ratio is ranked higher than
61% of the 161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.67 vs. RDY: 33.98 )
Ranked among companies with meaningful Shiller PE Ratio only.
RDY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 33.77  Med: 58.68 Max: 72.5
Current: 33.98
33.77
72.5
Current Ratio 1.11
RDY's Current Ratio is ranked lower than
86% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. RDY: 1.11 )
Ranked among companies with meaningful Current Ratio only.
RDY' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.8 Max: 5.29
Current: 1.11
1.04
5.29
Quick Ratio 0.79
RDY's Quick Ratio is ranked lower than
85% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. RDY: 0.79 )
Ranked among companies with meaningful Quick Ratio only.
RDY' s Quick Ratio Range Over the Past 10 Years
Min: 0.68  Med: 1.37 Max: 4.3
Current: 0.79
0.68
4.3
Days Inventory 183.77
RDY's Days Inventory is ranked lower than
94% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. RDY: 183.77 )
Ranked among companies with meaningful Days Inventory only.
RDY' s Days Inventory Range Over the Past 10 Years
Min: 77.02  Med: 143.49 Max: 248.16
Current: 183.77
77.02
248.16
Days Sales Outstanding 98.67
RDY's Days Sales Outstanding is ranked lower than
73% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. RDY: 98.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
RDY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 42.16  Med: 90.62 Max: 124.17
Current: 98.67
42.16
124.17

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.78
RDY's Dividend Yield % is ranked lower than
78% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. RDY: 0.78 )
Ranked among companies with meaningful Dividend Yield % only.
RDY' s Dividend Yield % Range Over the Past 10 Years
Min: 0.31  Med: 0.64 Max: 0.97
Current: 0.78
0.31
0.97
Dividend Payout Ratio 0.35
RDY's Dividend Payout Ratio is ranked higher than
50% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.35 vs. RDY: 0.35 )
Ranked among companies with meaningful Dividend Payout Ratio only.
RDY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.14 Max: 0.99
Current: 0.35
0.04
0.99
3-Year Dividend Growth Rate 13.30
RDY's 3-Year Dividend Growth Rate is ranked higher than
61% of the 285 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. RDY: 13.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
RDY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -10.6  Med: 17 Max: 171.4
Current: 13.3
-10.6
171.4
Forward Dividend Yield % 0.78
RDY's Forward Dividend Yield % is ranked lower than
80% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.59 vs. RDY: 0.78 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.46
RDY's 5-Year Yield-on-Cost % is ranked lower than
65% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.09 vs. RDY: 1.46 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
RDY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.58  Med: 1.19 Max: 1.81
Current: 1.46
0.58
1.81
3-Year Average Share Buyback Ratio -0.20
RDY's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. RDY: -0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RDY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6.6  Med: -0.2 Max: 0
Current: -0.2
-6.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 5.45
RDY's Price-to-Tangible-Book is ranked lower than
67% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. RDY: 5.45 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RDY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.07  Med: 6.29 Max: 83.42
Current: 5.45
3.07
83.42
Price-to-Intrinsic-Value-Projected-FCF 2.37
RDY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
50% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. RDY: 2.37 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
RDY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.47  Med: 3.07 Max: 4.58
Current: 2.37
1.47
4.58
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.13
RDY's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
95% of the 80 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.33 vs. RDY: 3.13 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.91
RDY's Price-to-Median-PS-Value is ranked higher than
67% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. RDY: 0.91 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RDY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 1.05 Max: 1.78
Current: 0.91
0.38
1.78
Price-to-Peter-Lynch-Fair-Value 4.03
RDY's Price-to-Peter-Lynch-Fair-Value is ranked lower than
88% of the 174 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. RDY: 4.03 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
RDY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.55  Med: 1.12 Max: 4.98
Current: 4.03
0.55
4.98
Price-to-Graham-Number 2.85
RDY's Price-to-Graham-Number is ranked lower than
67% of the 408 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. RDY: 2.85 )
Ranked among companies with meaningful Price-to-Graham-Number only.
RDY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.67  Med: 2.66 Max: 11.05
Current: 2.85
1.67
11.05
Earnings Yield (Greenblatt) % 3.34
RDY's Earnings Yield (Greenblatt) % is ranked higher than
51% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. RDY: 3.34 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RDY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.4  Med: 5.2 Max: 11.6
Current: 3.34
0.4
11.6
Forward Rate of Return (Yacktman) % 10.69
RDY's Forward Rate of Return (Yacktman) % is ranked higher than
50% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.72 vs. RDY: 10.69 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
RDY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -9.4  Med: 2 Max: 48.4
Current: 10.69
-9.4
48.4

More Statistics

Revenue (TTM) (Mil) $2,105
EPS (TTM) $ 1.10
Beta0.10
Short Percentage of Float0.00%
52-Week Range $37.30 - 54.73
Shares Outstanding (Mil)165.73

Analyst Estimate

Mar18
Revenue (Mil $)
EPS ($) 2.10
EPS without NRI ($) 2.10
EPS Growth Rate
(Future 3Y To 5Y Estimate)
14.61%
Dividends per Share ($) 0.28
» More Articles for RDY

Headlines

Articles On GuruFocus.com
Agios and Aurigene Enter into Exclusive License Agreement for Novel Small Molecules for Cancer Metab Apr 27 2017 
Stocks Reach Their 3-Year Lows Mar 25 2017 
Growing Generic Drug Market a Good Opportuity for 2 India Firms May 30 2016 
Ken Fisher Sells Shares of PMC Sierra, Alphabet During 4th Quarter Jan 15 2016 
Emerging Market Stocks To Watch Out For Feb 17 2015 
Should You Buy Actavis? Mar 18 2014 
Dr. Reddy’s Laboratories: Should Continue to Gain Market Share in Lucrative Markets May 25 2012 
5 Mid-Cap Healthcare Dividend Stocks with Perfect Earnings Growth Dec 05 2011 
Abbott Laboratories and the “India Cure” for the Ailing Pharmaceutical Industry May 26 2010 

More From Other Websites
Xgeva Is Expected to See Robust Revenue Performance in 2017 May 24 2017
Elite Pharmaceuticals Acquires Trimipramine ANDA May 22 2017
Dr. Reddy's Laboratories Announces USFDA Approval for the Launch of Doxorubicin Hydrochloride... May 17 2017
Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q4 May 15 2017
Doctor Reddy's posts 4Q profit May 12 2017
Dr. Reddy’s Q4 and FY17 Financial Results May 12 2017
Agios and Aurigene Enter into Exclusive License Agreement for Novel Small Molecules for Cancer... Apr 27 2017
Dr. Reddy's Laboratories Announces the Launch of Ezetimibe and Simvastatin Tablets in the U.S.... Apr 27 2017
Dr. Reddy's Laboratories Announces the Launch of Progesterone Capsules in the U.S. Market Apr 21 2017
New Strong Sell Stocks for April 20th Apr 20 2017
India's Dr Reddy's says U.S. FDA raises fresh concerns at Srikakulam drug plant Apr 04 2017
Dr. Reddy’s and Integra LifeSciences Enter into an Agreement to Market and Distribute DuraGen... Mar 27 2017
Stocks Reach Their 3-Year Lows Mar 25 2017
CytoSorbents Announces CytoSorb® Partnership with Dr. Reddy's Laboratories Mar 16 2017
Dr. Reddy's Expands Commercial Operations in Europe Feb 08 2017
BioMarin sues to stop generic version of its $90K-a-year drug Feb 07 2017
Dr. Reddy’s Laboratories Ltd. :RDY-US: Earnings Analysis: Q3, 2017 By the Numbers : February 7,... Feb 07 2017
Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q3 Feb 06 2017
Dr. Reddy’s Q3 and 9M FY17 Financial Results Feb 04 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)